Navigation Links
New Pre-Clinical Data on OmniGuide's BeamPath NEURO(TM) Demonstrates Precise Cutting in Brain Tissue
Date:7/6/2009

CAMBRIDGE, Mass., July 6 /PRNewswire/ -- OmniGuide, Inc., the developer of the first and only flexible CO2 laser fiber based on breakthrough photonic bandgap technology, today announced the results of a pre-clinical study comparing the Company's fiber scalpels to conventional incision methods in neurosurgery. In the study, surgeons from the Barrow Neurological Institute reported that careful studies of incisions produced in live brain tissue with fiber delivered CO2 laser radiation produced precise cuts while minimally effecting adjacent brain tissue when compared with a widely used reference technique. The study, led by Drs. Mark Preul, Robert W. Ryan, and Robert Spetzler of the Neurosurgery Research Laboratory, Barrow Neurological Institute, in Phoenix, Arizona, was presented at the annual conference of the American Academy of Neurological Surgeons in San Diego, California.

"The study demonstrates that the flexible CO2 laser fiber was easy to use and manipulate under the operating microscope, could be accurately aimed and created precise incisions without the need to touch or manipulate the tissue," said Dr. Preul, Director of the Barrow's Neurosurgical Research Laboratory. "The device also allows surgeons to cut and coagulate with a single instrument. Given the high absorption of the CO2 laser in water, a smaller area of tissue is affected as deeper incisions are made which indicates that the BeamPath NEURO could be a valuable new tool added to the neurosurgical armamentarium."

CO2 lasers were first used in neurosurgery in 1970 but were never widely adopted because the systems available for delivering the laser energy were awkward and surgeons were limited to "line of sight" procedures. OmniGuide's BeamPath fiber is based on breakthrough fiber technology developed at MIT and exclusively licensed to OmniGuide. The company manufactures the world's first flexible fibers for CO2 laser surgery. BeamPath fibers empower surgeons to perform delicate cutting and coagulation with minimal thermal tissue damage and ultimate maneuverability, a major advantage.

"The study conducted by surgeons from the Barrow Neurological Institute, a world renowned medical center for brain and spine surgery, provides further validation of the safety and efficacy of the BeamPath fiber in neurosurgery. The ability to precisely and hemostatically cut in the brain while minimizing loss of precious brain tissue has a real potential for improving brain tumor removal efficacy," said Yoel Fink, president and CEO of OmniGuide. "Since the launch of the BeamPath NEURO, we've seen strong demand for our technology and it is becoming more widely available to a new patient population that will benefit significantly."

About OmniGuide, Inc.

OmniGuide, Inc., is the worldwide leader in precision optical scalpels for minimally invasive surgery. OmniGuide CO2 laser fiber products are clinically targeted disposable optical scalpels optimized for specific surgical procedures. The Company has recently introduced a line of fiber-enabled, portable, low-cost CO2 lasers for use in operating rooms and surgical suites. The Company designs and manufactures its fiber products in Cambridge, Mass. based on multi-material photonic bandgap fiber technology exclusively licensed from MIT. The Company distributes its products in the U.S. through a direct sales force and in Europe through distribution partners. OmniGuide is committed to developing products that improve and expand surgical treatment options, enhance clinical outcomes, and reduce treatment complexity and cost.

OmniGuide has several leading-edge flexible laser fiber scalpels for use in both hospital and office settings; leading brands include the BeamPath(TM) ENT for laryngology, airway and head and neck procedures and BeamPath(TM) OTO for otology procedures and the BeamPath(TM) NEURO for neurosurgery. Additional information about OmniGuide may be found at www.omni-guide.com.

    Contacts:  Dana Conti/Caitlin Hunt
               Schwartz Communications, Inc.
               781.684.0770
               omniguide@schwartz-pr.com


'/>"/>
SOURCE OmniGuide, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. XTL Biopharmaceuticals Announces Presentation of Novel Pre-Clinical Inhibitors of Hepatitis C at an Upcoming International Scientific Conference
2. Amarin Announces Publication of Pre-Clinical Memory Data in Journal of Neurochemistry
3. EpiCept to Present Pre-clinical Advances of Myc Oncogene Directed Drug Discovery at Assays and Cellular Targets Conference
4. Genmab Announces HuMax-CD32b Pre-Clinical Program
5. Phosphagenics Reports Superior Pre-clinical Cholesterol Results from APA-01 and Atorvastatin Combination
6. Anavex 7-1037 reduces rate of cancer tumor growth 69% in pre-clinical studies, compared to currently marketed drug Dacarbazine showing no measurable activity
7. Morria Biopharmaceuticals Plc Announces Results From its Pre-Clinical Screening of Novel Anti-Inflammatory Compounds
8. CorMatrix Announces Pre-Clinical Data Suggesting Next Generation ECM Technology(TM) Can Improve Cardiac Function
9. Michael J. Fox Foundation Commits Up To $5 Million for Pre-Clinical Drug Development Under Industry-Exclusive Therapeutics Development Initiative
10. Biovista Inc. Announces Positive Efficacy Results in a Pre-Clinical Trial of its BVA-101 Repositioned Drug for Multiple Sclerosis
11. Pre-Clinical Data on CEA-specific BiTE Antibody Published in Journal of Immunotherapy Demonstrate Potent Control of Tumor Growth
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... /PRNewswire/ - FACIT has announced the creation of ... company, Propellon Therapeutics Inc. ("Propellon" or "the Company"), ... portfolio of first-in-class WDR5 inhibitors for the treatment ... represent an exciting class of therapies, possessing the ... cancer patients. Substantial advances have been achieved with ...
(Date:6/23/2016)... MONICA, Calif. , June 23, 2016  The Prostate Cancer Foundation ... pioneer increasingly precise treatments and faster cures for prostate cancer. Members of the ... institutions across 15 countries. Read More About the Class ... ... ...
(Date:6/23/2016)... ... 23, 2016 , ... STACS DNA Inc., the sample tracking software company, today ... Laboratory, has joined STACS DNA as a Field Application Specialist. , “I am ... and COO of STACS DNA. “In further expanding our capacity as a scientific integrator, ...
(Date:6/23/2016)... -- Andrew D Zelenetz , ... Published recently in Oncology & ... Andrew D Zelenetz , discusses the fact ... placing an increasing burden on healthcare systems worldwide, ... the patents on many biologics expiring, interest in ...
Breaking Biology Technology:
(Date:4/15/2016)... 15, 2016  A new partnership announced today ... underwriting decisions in a fraction of the time ... and high-value life insurance policies to consumers without ... With Force Diagnostics, rapid testing (A1C, Cotinine and ... (blood pressure, weight, pulse, BMI, and activity data) ...
(Date:4/13/2016)... , April 13, 2016  IMPOWER physicians supporting Medicaid ... setting a new clinical standard in telehealth thanks to ... leveraging the higi platform, IMPOWER patients can routinely track ... and body mass index, and, when they opt in, ... convenient visit to a local retail location at no ...
(Date:3/29/2016)... BOCA RATON, Florida , March 29, 2016 /PRNewswire/ ... ("LegacyXChange" or the "Company") LegacyXChange "LEGX" and SelectaDNA/CSI Protect ... Synthetic DNA in ink used in a variety of ... preventing theft. Buyers of originally created collectibles from athletes ... authenticity through forensic analysis of the DNA. ...
Breaking Biology News(10 mins):